Search Results - "Diamond, Robert"

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial by Cornillie, Freddy, Hanauer, Stephen B, Diamond, Robert H, Wang, Jianping, Tang, Kezhen L, Xu, Zhenhua, Rutgeerts, Paul, Vermeire, Séverine

“…Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohn's disease who stop responding to infliximab…”
Get more information

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease by Colombel, Jean Frédéric, Sandborn, William J, Reinisch, Walter, Mantzaris, Gerassimos J, Kornbluth, Asher, Rachmilewitz, Daniel, Lichtiger, Simon, D'Haens, Geert, Diamond, Robert H, Broussard, Delma L, Tang, Kezhen L, van der Woude, C. Janneke, Rutgeerts, Paul

“…In this randomized trial comparing infliximab, azathioprine, and combination therapy in adults with moderate-to-severe Crohn's disease, infliximab and…”
Get full text

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial by Peyrin-Biroulet, Laurent, Reinisch, Walter, Colombel, Jean-Frederic, Mantzaris, Gerassimos J, Kornbluth, Asher, Diamond, Robert, Rutgeerts, Paul, Tang, Linda K, Cornillie, Freddy J, Sandborn, William J

“…The Crohn's Disease Activity Index (CDAI) has been criticised due to heavy weighting on subjective clinical symptoms. C-reactive protein (CRP) and endoscopic…”
Get more information

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry by Lichtenstein, Gary R, Feagan, Brian G, Cohen, Russell D, Salzberg, Bruce A, Diamond, Robert H, Langholff, Wayne, Londhe, Anil, Sandborn, William J

“…We assessed potential associations between malignancy and antitumor necrosis factor therapy in patients with Crohn's disease (CD), as this relationship is…”
Get full text

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry by LICHTENSTEIN, Gary R, FEAGAN, Brian G, COHEN, Russell D, SALZBERG, Bruce A, DIAMOND, Robert H, PRICE, Samiyeh, LANGHOLFF, Wayne, LONDHE, Anil, SANDBORN, William J

“…The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD). We prospectively evaluated CD…”
Get full text

A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease by Lichtenstein, Gary R, Rutgeerts, Paul, Sandborn, William J, Sands, Bruce E, Diamond, Robert H, Blank, Marion, Montello, Jennifer, Tang, Linda, Cornillie, Freddy, Colombel, Jean-Frédéric

“…The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD)…”
Get full text

A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease by Kotlyar, David S, Osterman, Mark T, Diamond, Robert H, Porter, David, Blonski, Wojciech C, Wasik, Mariusz, Sampat, Sami, Mendizabal, Manuel, Lin, Ming V, Lichtenstein, Gary R

“…Background & Aims Hepatosplenic T-cell lymphoma (HSTCL) is a rare and usually fatal lymphoma that primarily affects men younger than 35 years old. Treatment of…”
Get full text

Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC by Ferrante, Marc, Colombel, Jean–Frederic, Sandborn, William J, Reinisch, Walter, Mantzaris, Gerassimos J, Kornbluth, Asher, Rachmilewitz, Daniel, Lichtiger, Simon, D'Haens, Geert R, van der Woude, Christien J, Danese, Silvio, Diamond, Robert H, Oortwijn, Alessandra Faria, Tang, Kezhen L, Miller, Michael, Cornillie, Freddy, Rutgeerts, Paul J

“…Background & Aims Mucosal healing might alter midterm and long-term outcomes of patients with Crohn's disease (CD) and has become an important end point in…”
Get full text

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease by Rutgeerts, Paul, MD, PhD, Diamond, Robert H., MD, Bala, Mohan, PhD, Olson, Allan, MD, Lichtenstein, Gary, MD, Bao, Weihang, PhD, Patel, Kamlesh, MS, Wolf, Douglas C., MD, Safdi, Michael, MD, Colombel, Jean Frederic, MD, Lashner, Bret, MD, Hanauer, Stephen B., MD

“…Background The endoscopic substudy of the ACCENT I (•••) Crohn's disease trial examined the effects of infliximab on mucosal inflammation and mucosal healing,…”
Get full text

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease by Hanauer, Stephen B, Wagner, Carrie L, Bala, Mohan, Mayer, Lloyd, Travers, Suzanne, Diamond, Robert H, Olson, Allan, Bao, Warren, Rutgeerts, Paul

“…The effect of different treatment regimens on antibody responses to infliximab and their clinical significance was examined by using data from ACCENT I…”
Get more information

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry by Lichtenstein, Gary R, Feagan, Brian G, Cohen, Russell D, Salzberg, Bruce A, Diamond, Robert H, Chen, Donny M, Pritchard, Michelle L, Sandborn, William J

“…Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed. We prospectively evaluated patients for prespecified…”
Get more information

Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease by LICHTENSTEIN, Gary R, OLSON, Allan, SANDBORN, William J, TRAVERS, Suzanne, DIAMOND, Robert H, CHEN, Donny M, PRITCHARD, Michelle L, FEAGAN, Brian G, COHEN, Russell D, SALZBERG, Bruce A, HANAUER, Stephen B

“…Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis,…”
Get full text

Quality of life after proctocolectomy with lleoanal anastomosis for patients with ulcerative colitis by LIECHTENSTEIN, Gary R, COHEN, Russell, YAMASHITA, Beverly, DIAMOND, Robert H

Get full text

Hepatosplenic T-Cell Lymphoma in Inflammatory Bowel Disease: A Possible Thiopurine-Induced Chromosomal Abnormality by KOTLYAR, David S, BLONSKI, Wojciech, DIAMOND, Robert H, WASIK, Mariusz, LICHTENSTEIN, Gary R

Get full text

Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis by Lichtenstein, Gary R, Cohen, Russell, Yamashita, Beverly, Diamond, Robert H

“…Ulcerative colitis, a chronic inflammatory disease of the rectal and colonic mucosa, affects approximately 250,000 to 500,000 people in the United States, with…”
Get full text

Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease by Montgomery, Michael, van Santen, Marije M, Biemond, Bart J, Diamond, Robert H, Pals, Steven T

“…Hepatosplenic T-cell lymphoma (HSTCL) is a rare malignancy of unknown incidence that has been associated with immune-mediated disease. This study explored the…”
Get full text

On the updated ECCO consensus guidelines for medical management of Crohn's disease by Esser, Dirk, Cornillie, Freddy, Diamond, Robert H., Spiegel, Robert J.

Get full text

Preparing for Promotion and Tenure Review; A Faculty Guide by Diamond, Robert M

“…This guide enumerates important questions to ask and issues to consider in approaching promotion and/or tenure review, whether at large universities or small…”
Get more information

Aligning Faculty Rewards with Institutional Mission. Statements, Policies, and Guidelines by Diamond, Robert M

“…This book provides guidelines for developing a coherent faculty rewards system, starting with the articulation of institutional priorities and following the…”
Get more information

Designing and Improving Courses and Curricula in Higher Education: A Systematic Approach by Diamond, Robert M

“…A systematic approach to the improvement of courses, programs and curricula in higher education is presented in the following chapters: (1) "Benefits of a…”
Get more information